Digital Asset DirectImmuPharma "looking forward with quiet confidence" to FDA response
ImmuPharma PLC
Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 24, 2023 11:08 AM Eastern Daylight Time
Video
Digital Asset Direct
Digital Asset DirectVoyager Life "now capable of dealing with multinational customers"
Voyager Life PLC
Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 24, 2023 11:03 AM Eastern Daylight Time
Video
Digital Asset DirectOxford Cannabinoid Technologies: Phase 1 approval for lead chronic pain drug
Oxford Cannabinoid Technologies Holdings PLC
Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 24, 2023 10:59 AM Eastern Daylight Time
Video
News ReleaseIntus Care Announces Data Partnership with North Carolina PACE Association
Intus Care
Intus Care, a pioneer in advanced software and data-driven solutions for geriatric healthcare, announced today its collaboration with the North Carolina PACE Association. NC PACE advocates for PACE (Programs of All-Inclusive Care for the Elderly) and strives to broaden its reach and success across the state. Intus Care contributes an innovative blend of automated software and Integrated Care Services (ICS) to this partnership. Already partnering with the majority of North Carolina PACE programs, Intus Care will now automate all benchmark reporting for partnered programs, while assuming responsibility for submissions from non-partnered programs. Utilizing this data, the Intus Care team will collaborate with the NC PACE Association to develop benchmarking reports, conduct data analysis, and present insights to the Association and its members. “We are pleased for this opportunity to work with such an innovative Association as they consistently find creative ways to empower their membership and facilitate the model’s success throughout the state,” said Intus Care Chief Strategy Officer Laura Ferrara. The NC PACE Association will collaborate with Intus Care's team of PACE specialists, led by Laura, to structure benchmarking reporting procedures and analyze data at the organizational, state, and national levels. Through quarterly presentations to the NC PACE Association and its members, Laura and the ICS team will showcase the benchmarking analysis, pinpoint areas of achievement and potential, and propose best practice interventions to empower performance. “The NC PACE Association, along with our NC PACE organizations, believes that reliable data leads to informed decisions. This, in turn, assists us with our mission: providing integrated managed care for the elderly and expanding PACE services statewide,” said Liz Bradsher, Executive Director of the NC PACE Association. "Intus Care shares our mission and we are eager to see the impact of this relationship within our NC PACE organizations, as well as within the state.” About Intus Care Intus Care empowers PACE organizations nationwide through automated software and PACE expert consulting. Our PACE-focused analytics platform improves clinical decision making and data accessibility, while our Integrated Care Service experts collaborate with programs to improve Compliance, Quality, Utilization, and more through a hands-on, data-driven approach. Intus Care currently works with over 40 PACE programs across 16 states and closed a $14.1M Series A in Q4 of 2022. Visit our website to learn more and to sign up for our newsletter intuscare.com. Contact Details SVM Public Relations Jordan Bouclin and Alison Matthiessen +1 401-490-9700 intuscare@svmpr.com Company Website https://www.intuscare.com/
May 24, 2023 10:00 AM Eastern Daylight Time
News ReleaseBioNTech's mRNA Vaccine Shows Early Potential Against Pancreatic Cancer
MarketJar
One of the most stubborn, deadly cancers is pancreatic cancer. What if individualized mRNA vaccinations could support the immune system's defense? One of the deadliest forms of cancer around, pancreatic cancer is estimated to kill 88% of patients. It’s also one of the most recurrent cancers, with roughly 90% of patients experiencing a relapse within seven to nine months after surgery. Fortunately, a recent study of an mRNA vaccine for pancreatic cancer patients has provided a glimpse of hope. Scientists at Memorial Sloan Kettering (MSK) Cancer Center in New York just published the results of a small study that the group conducted in partnership with Germany’s BioNTech on pancreatic cancer patients over several years. The study used a pancreatic cancer mRNA vaccine tailored to each patient’s tumor to potentially help provoke an immune response. What’s revolutionary about the vaccines is that the German scientists tailored them to the mutated proteins on the surface of cancer cells instead of a mix of tumor and normal cells, which has been the method tried for decades. The cells were extracted from patients’ tumors by researchers at Memorial Sloan and sent to BioNTech, the company that created the highly-effective COVID-19 vaccine alongside Pfizer. Among the participants in the study, half of the patients’ immune systems learned how to recognize and fight off the cancer cells and showed no signs of relapse during the 18 months they were tracked. While promising, personalized mRNA cancer vaccines are still in their infancy and are too costly to be broadly used. Right now, regular cancer screening remains the best method for detecting cancers, however there are currently no screening tests for pancreatic cancer. Fortunately, that could soon change thanks to Mainz Biomed (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer Developing Early Screening Tests for Colon and Pancreatic Cancers On May 10, Mainz Biomed announced a partnership with Microba Life Sciences for the creation of PancAlert in addition to early colon cancer diagnostics. The technical characteristics of a novel pancreatic cancer screening test with DNA and microbiota indications should be enhanced. As part of the agreement, the two companies will conduct a pilot research project utilizing Microba’s proprietary metagenomic sequencing technology and bioinformatic tools in an effort to discover novel microbiome biomarkers to detect pancreatic cancer. The project, which is expected to run until late 2023, will use Microba's Community Profiler (MCP), a proprietary metagenomic platform technology that has proven to be a best-in-class research tool that can produce comprehensive and accurate species profiles of gastrointestinal samples. Mainz Biomed (NASDAQ:MYNZ) is also focused on commercializing its flagship product ColoAlert, a highly efficacious and simple-to-use detection test for colorectal cancer (CRC) that is already available in select international territories. In Q1 2023, the company also launched a corporate health program in Germany by integrating into BGM, a well-established corporate health program that provides services to employees at 48 of the 50 largest companies in Germany. On May 24, Mainz Biomed announced initial results from its colorectal cancer screening campaign with Zöller-Kipper GmbH through its BGM partnership. In April 2023, Zöller-Kipper selected ColoAlert for its corporate health program, which includes over 2,500 employees. According to the results, employees found the online patient portal easy-to-use and convenient and were able to readily access the portal, request a kit and securely receive results within five days. In order to process the ColoAlert PCR test kit, Mainz Biomed has added Eurofins GeLaMed to its network of lab partners. Eurofins GeLaMed is a division of the global laboratory company Eurofins Scientific, which conducts 450 million tests annually and has over 61,000 employees in 61 nations. Germany is home to four of its locations. Advancing Towards FDA Approval to Bring ColoAlert to the US Market Over the last few months, Mainz Biomed has continued to prepare for patient enrollment in its pivotal clinical trial for ColoAlert after successfully completing its pre-submission process with the FDA. ColoAlert will be examined in the FDA-registered trial "ReconAAsense" in order to obtain commercial approval in the United States. The company's business objective is to create scalable distribution across the nation once it receives approval through a cooperative partner program with regional and national laboratory service providers. Learn more about Mainz Biomed (NASDAQ:MYNZ) and its activities by clicking on this link. Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Mainz Biomed NV. Market Jar Media Inc. has or expects to receive from Mainz Biomed NV’s Digital Marketing Agency of Record (Native Ads Inc.) eighty nine thousand seven hundred sixty four USD for 12 days (9 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Mainz Biomed NV’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Mainz Biomed NV’s industry; (b) market opportunity; (c) Mainz Biomed NV’s business plans and strategies; (d) services that Mainz Biomed NV intends to offer; (e) Mainz Biomed NV’s milestone projections and targets; (f) Mainz Biomed NV’s expectations regarding receipt of approval for regulatory applications; (g) Mainz Biomed NV’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Mainz Biomed NV’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Mainz Biomed NV’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Mainz Biomed NV’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Mainz Biomed NV’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Mainz Biomed NV’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Mainz Biomed NV to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Mainz Biomed NV’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Mainz Biomed NV’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Mainz Biomed NV’s business operations (e) Mainz Biomed NV may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Mainz Biomed NV undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Mainz Biomed NV nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Mainz Biomed NV nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Mainz Biomed NV or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Mainz Biomed NV or such entities and are not necessarily indicative of future performance of Mainz Biomed NV or such entities. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com
May 24, 2023 09:00 AM Eastern Daylight Time
Image
News Release‘Ready for Ron’ Now ‘Ready to Win’
Ready for Ron
For more than a year, Ready for Ron, an independent group working to Draft Florida Governor Ron DeSantis to run for President, actively built support for his candidacy. A petition with more than 250,000 signatures (and a lawsuit against the Federal Election Commission to share it) tens of thousands of TV and online ads, along with millions of phone calls, mail pieces, and emails, and a grassroots and coalitions program has done its job - Governor Ron DeSantis is expected to soon announce he’s running for President. With Governor DeSantis about to become an official candidate, Ready for Ron is changing its name to ‘Ready to Win’ to reflect its singular mission to nominate and elect Ron DeSantis to win in 2024. “We spent an entire year running thousands of TV ads, millions of mailings, and tens of millions of online, email, and social connections to drive the narrative – Ron DeSantis will be our next President,” stated Ed Rollins, Ready to Win’s Chief Political Strategist. “We built an infrastructure. We completely changed the discussion. With a quarter million petition signers calling for him to run we are thrilled that we see our goal achieved - Ron DeSantis entering the Presidential race. He may well be the only leader who can defeat Joe Biden.” In addition to its outreach and engagement initiatives, Ready for Ron worked with Impact Social to analyze the online and social media discussion in relation to Ron DeSantis and Donald Trump among swing voters. The data clearly and consistently shows Ron DeSantis can beat Joe Biden, and Donald Trump simply can’t. Additional data research with multiple vendors covering more than 19 million voters affirms these findings. “Winning the nomination and the general election requires us all to work together to build this movement and save our nation,” stated Ready to Win Counsel, Dan Backer. “Our groundbreaking research debunked the bad polling plaguing Republicans for more than eight years. Using cutting edge massive data monitoring proves what everyone already knows - Donald Trump’s supporters are loyal and loud, but confined to only a sliver of the population that cannot grow. Moderate, swing, and independent voters are not coming back to Trump, ever, and he cannot possibly win the general Election – Ron DeSantis can.” “Voters young and old both know Governor DeSantis has a proven track record of standing up for America’s values. He is committed to defending the rights of parents, getting inflation and government spending under control, and solving the problems the radical left is causing. He dares to say no to the bullies, no matter how powerful they may seem. He can deliver safe streets, sane schools, and a soaring economy,” stated Gabriel Llanes, Executive Director of Ready to Win. “DeSantis is much more than a politician with savvy instincts; he is a public servant through and through. No ego to get in the way because he is about results.” “We will continue our ground-up grassroots efforts in key primary states, doing the hard work to train and mobilize a volunteer army to nominate, and elect, our next great American president,” Rollins continued. We feel DeSantis is well prepared to be the candidate to win the Republican nomination and beat President Biden. We are officially, Ready to Win!” ### For more information or to schedule an interview with a Ready to Win spokesperson, please contact Dan Rene at 202-329-8357 or dan@readyforron.com. Contact Details Ready to Win Dan Rene +1 202-329-8357 dan@readyforron.com Company Website https://www.readyforron.com/
May 23, 2023 02:50 PM Eastern Daylight Time
Digital Asset DirectCreo Medical Group "gaining a level of acceptance" in endoscopy
Creo Medical Group PLC
Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 23, 2023 11:15 AM Eastern Daylight Time
Video
News ReleaseQ-Vant Biosciences Announces Positive Study Results for Its Sustainable Quillaja-Based Vaccine Adjuvant, Q-VET-S®, in Kansas State’s Classic Swine Fever Vaccine
Q-Vant Biosciences
Q-Vant Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced very positive results comparing Q-Vant's sustainable saponin-based adjuvant, Q-VET-S®, to Croda's Quil-A® adjuvant. These results were obtained through a collaborative study with Kansas State University, utilizing their subunit classic swine fever (CSF) vaccine. The CSF vaccine was developed by Kansas State professor Dr. Jishu Shi. Dr. Shi also serves as the director of the Center for Vaccine Evaluation, where he and his team are working on novel vaccine and diagnostic strategies aimed at better control and prevention measures targeting swine infectious diseases. This includes porcine reproductive and respiratory syndrome (PRRS), classical swine fever virus (CSF), African swine fever (ASF), and other emerging viral diseases of swine. Juan Jose Albarran, the chief commercial officer of Q-Vant Biosciences, said, "The development of Q-VET-S® and its proven effect marks a major milestone in the field of vaccine adjuvants. Our cutting-edge technology not only ensures a reliable supply for the pharmaceutical sector but also addresses the environmental concerns associated with Quillaja Saponaria harvesting. By focusing on sustainability, we are playing a significant role in protecting Chile's forests while simultaneously advancing global animal and human health." For more information about Q-Vant Biosciences and Q-VET-S, please visit www.q-vant.com. About Kansas State University: Kansas State University, established in 1863, is a leading public research university with a mission to foster excellent teaching, research, and service that develops a highly skilled and educated citizenry necessary to advancing the well-being of Kansas, the nation, and the international community. The university is committed to advancing knowledge through research and creative activities, developing leaders, and contributing to the global community's well-being. About Q-VANT Biosciences Q-VANT is a privately held biosciences company that has solved the supply chain problem of QS-21 and other Quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. The companyâs next-generation technology platform combines computational learning techniques with a proprietary multi-step purification process to increase the supply of QS-21 by more than 1,000 â enabling the production of billions of doses annually to meet todayâs increasing global market demand. Led by a team with unrivaled experience in vaccine and adjuvant development, manufacturing and global regulatory requirements, and with world-class knowledge in Quillaja saponin supply chain, agronomy, extraction and purification, Q-VANT is the first company that is vertically integrated to combine a secured sustainable Quillaja raw material supply with pharma cGMP commercial-scale production of QS-21 and other saponin-based adjuvants. For more information, visit www.q-vant.com. Contact Details Q-Vant Biosciences Doug Klaiber dklaiber@q-vant.com Company Website https://q-vant.com/
May 23, 2023 10:00 AM Eastern Daylight Time
News ReleasePathPresenter Surpasses 50,000 Global Users
PathPresenter
PathPresenter, the global image sharing platform for pathology, today announced that their free public platform ( https://pathpresenter.net/ ) now has more than 50,000 registered users in 172 countries. Nearly 7,000 users have joined the pathology image sharing community in the past 12 months. Founded by dermatopathologist and digital pathology innovator, Dr. Rajendra Singh, PathPresenter has become the go-to, on-line community for pathologists, residents, fellows, scientists, and researchers who want to easily upload, view, and share whole slide images with their colleagues, as well as access curated image datasets from trusted experts. With over 100,000 hours of real-world usage, users have embraced PathPresenter’s best-in-class, lag-free imaging performance, super-easy sharing of images with colleagues (through URL links and/or QR codes), and the platform’s pathologist-built functionality. The viral popularity of PathPresenter public has helped spur the adoption of PathPresenter’s robust and secure enterprise platform at tier-one institutions, becoming one of the fastest growing digital pathology enterprise workflow platforms for use in clinical care, education, and research. The “instant familiarity” of the PathPresenter platform and brand – used by pathologists at almost every major hospital in the world – translates into higher rates of adoption and user enthusiasm among pathologists and therefore a higher return on investment for institutions implementing new digital pathology enterprise workflows. “Within 5 years, the majority of the world’s 1 billion glass slides produced each year will be digital. PathPresenter is building the roads and bridges to enable petabytes (soon to be exabytes) of digital pathology images to flow easily and securely within and between institutions to advance patient care, research, and pathology education,” said Patrick Myles, Chief Executive Officer of PathPresenter. “I would like to thank our community of 50,000+ PathPresenter users around the world for their unwavering support and their continued valuable input into the platform.” “It is the feedback from great colleagues from around the world that has helped us build practical workflow solutions to use digital pathology in all three pillars of our work: clinical care of our patients by providing accurate diagnosis with prognostic information, educating new pathologists, and accelerating research for better care of patients,” added PathPresenter founder, Dr. Rajendra Singh. “We will continue to work tirelessly with colleagues, institutions, and other vendors to ensure we can truly revolutionize our field and make it the center of personalized medicine.” About PathPresenter PathPresenter is the global image sharing platform for pathology. We are on a mission to help democratize access to the world’s pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded in 2017 by dermatopathologist and digital pathology innovator, Dr. Rajendra Singh, PathPresenter has been adopted by 30+ tier one medical institutions for clinical care, education, and research, and has built a thriving community of 50,000+ users in 172 countries to easily view and share digital pathology images and knowledge. Learn more about pathpresenter.com. PathPresenter is available for primary diagnosis in the US during the COVID-19 public health emergency. In other countries, PathPresenter is intended for research and educational purposes only. Contact Details PathPresenter Cory Batenchuk - SVP of Operations +1 873-355-9913 cory@pathpresenter.com About PathPresenter PathPresenter is the global image sharing platform for pathology. We are on a mission to help democratize access to the world's pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded in 2017 by dermatopathologist and digital pathology innovator, Dr. Rajendra Singh, PathPresenter has been adopted by 30+ tier one medical institutions for clinical care, education, and research, and has built a thriving community of 50,000+ users in 172 countries to easily view and share digital pathology images and knowledge. Learn more about pathpresenter.com. Contact Details Cory Batenchuk +1 873-355-9913 cory@pathpresenter.com Company Website https://pathpresenter.com
May 23, 2023 10:00 AM Eastern Daylight Time
